Ahmed Abd Al Aziz, MD1, Nader Sh. Zaki, MD2,Karim G. Moustafa, MD3, M. Fathy Elshaal
Abdrabou N Mashhour, Haitham S.E. Omar, Ramy S. Abdelkader.
Hany MS Mikhail, Mohamed M Raslan, Mohamed Y Elbarmelgi, Ramy S. Abdelkader
Adel Morad Abdallah (M.D.)
Ahmed S.M. Omar, MD
H. Said1, Ahmed Khalil1, Ahmed Fathy Hilal2
Ragai S. Hanna1, George Abdelfady Nashed2, Gamal A Makhlouf 3, Nahed A Makhlouf 4, Manal El Sayed Abdelmooty 5
Ragai S. Hanna1 , George Abdelfady Nashed2,Ashraf, A Helmy 3, Gamal A Makhlouf4, Emad Z.K. Said5, Abdelraouf MS Abdelraouf 6
Ramy Mikhael Nageeb1, *, MD, and Shaban M. Abdel Mageed2, *, MD
Shawki M.K Sharouda1*; Ramy Mikhael Nageeb2*; MD and Shaban M. Abdel Mageed1*, MD
Sherif Abdel Halim MD, MRCS, Hanna Habib MD, Hossam Elsadek MD
Ahmed Morad, MD; Wael A Jumuah, MD; Hanna Habib, MD
Yasser El Ghamrini, MD. Karim Sabry Abdel Samee, MD, MRCS(Ed), Wael Abdel Aziem Gumuah, MD.
Anas Mashal MD; Abdallah Magdy MD,FRCS
Anas Mashal MD, *Abdallah Abdelwahed MD;**Hady Saleh Abou-Ashour, MD,MRCS
Single HCC with Compensated Liver: Best Surgical Strategy
Aim of the work: comparison of 1 year overall and recurrence free survival and complication between
patients offered Living Donor Liver Transplantation (LDLT) and patients offered Liver Resection (LR) in
management of single Hepatocellular carcinoma (HCC) less than 5cm in well compensated cirrhosis. Type
of study: cohort prospective study. Patients and method: This study includes 36 patients who had surgical
intervention for HCC between June 2013 and June 2016, sixteen patients underwent LDLT and 20 patients
underwent LR. They were then followed for up to 1 year with record the outcomes and complications. This
study was done in Ain Shams University Hospitals and Egypt Air Hospital. Results: Recurrence of HCC in
the resection group occurred in 4 patients (20%) These were managed by radiofrequency (RF), Transarterial Chemoembolization (TACE), re-resection and best supportive care. In the transplant group, there
was 1 case (6.2%) of HCC recurrence that was managed by sorafenib (P-value = 0.0431). Mortality in the
transplant group occurred in 2 cases (12.5%), [ 3rd week and 10th month]. In the resection group, there was
1 mortality (5%) [4th week] (P-value = 0.418). The overall complication rate between LDLT and LR was
nearly similar, but with a different pattern. In the transplantation group there were more vascular (12.5%
Vs 0%) and biliary (18.8% Vs 5%) complications and also complications related to immune-suppressant
like chest infection (18.8% Vs 5%) and renal impairment (6.2% Vs 5%). In resection group the main
complications were related to liver decompensation (25% Vs 0%), hepato-renal syndrome, and biliary leak
in major hepatectomy. Conclusion: LDLT is better than LR for single HCC < 5 cm regarding Disease free
survival (DFS) with no difference in overall survival (OS) in short term follow up. Postoperative morbidity
is nearly similar for both strategies as regard overall incidence but with a different pattern.
Key Words: Single HCC, Compensated Liver, Strategy.